Aspirin is common preventative therapy in patients at risk for cardiovascular diseases, yet
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Aspirin therapy is widely used in patients at risk of developing atherosclerosis and thrombosis. The therapeutic efficacy of aspirin in cardiovascular diseases (CVD) is attributed to its platelet-inhibitory function, which results from irreversible inhibition of cyclooxygenase (COX) activity and thromboxane generation (2, 33) . Although platelets are a rich source of the constitutive isoform of COX (COX-1), endothelial cells also express COX-1 in addition to the inducible isoform, COX-2. This likely accounts for evidence implicating endothelial cell COX-1 inhibition in the beneficial effects of aspirin (but not COX-2 inhibitors) on the inflammation associated with atherosclerotic lesions in apoE -/-and low density lipoprotein receptor deficient (LDLr -/-) mice (8, 25) . While the anti-inflammatory action of aspirin in this setting may also result from platelet inhibition (8) , non-steroidal anti-inflammatory drugs (NSAIDs) and their metabolites (i.e., salicylate) can directly interfere with adhesion of inflammatory cells to vascular endothelium, both in vitro (5, 11) and in vivo (1, 6) . Hypercholesterolemia, diabetes, hypertension, and other risk factors for CVD promote inflammatory and thrombogenic responses in lesion-prone arteries. Similar responses are detected in microvasculature prior to the development of atherosclerotic lesions and may render tissues even more vulnerable to ischemic tissue injury (30) . Nonetheless, it remains unclear whether COX-1 inhibition by aspirin or other agents can attenuate these deleterious adhesion-dependent microvascular responses to CVD risk factors, and which cell type (platelets, endothelial cell, or leukocytes) is the primary target of aspirin.
A major limitation to aspirin therapy is gastrointestinal (GI) bleeding from reduced production of COX-1-derived cytoprotective prostaglandins. A new series of nitric oxidereleasing NSAIDs have been developed to reduce aspirin-mediated GI damage while maintaining aspirin's desired anti-inflammatory and anti-thrombotic properties. NO-releasing aspirin 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) inhibits thrombus formation in vivo through a mechanism that appears to be largely dependent on NO release and partially related to a weak inhibitory effect on COX-1-dependent thromboxane A 2 (TXA 2 ) synthesis (34, 35, 36) . This NO-releasing NSAID also markedly suppresses formylmethionine-leucine-phenylalanine (fMLP)-induced leukocyte adhesion in rat mesenteric venules (37) , an effect that likely results from NO inhibition of leukocyte-endothelial cell adhesion (16) .
However, whether NO-releasing aspirin provides additional benefit to plain aspirin in modulating the microvascular responses to CVD risk factors, such as hypercholesterolemia, has not been assessed to date.
The overall objective of this study was to determine whether chronic aspirin therapy protects against hypercholesterolemia-induced microvascular dysfunction/injury. Specific questions addressed were whether 1) treatment with aspirin or the selective COX-1 inhibitor 5- as previously described (32) . The platelet isolation procedure yielded negligible contamination with other cellular components, and has no significant effect on activation state or viability (28, 32) . Platelets (100 x 10 6 ) were infused into recipient mice via the jugular vein over 5 min, yielding ~5% of the total murine platelet count. Platelets were allowed to circulate for 5 min prior to the observation and recording period. Scheffe's (post-hoc test). All values are reported as mean ± SEM, from 5-9 mice per group, and statistical significance was set at P<0.05.
Results
All HC groups exhibited increased total serum cholesterol concentration compared to their ND counterparts. Aspirin, NCX-4016, or SC560 treatment did not alter serum cholesterol levels ( Table 1) . Blood leukocyte and platelet counts were similar between groups ( Table 1) .
Aspirin inhibits HC-induced platelet and leukocyte adhesion: Our first objective was to determine whether aspirin altered the proinflammatory and prothrombogenic phenotype that is assumed by hypercholesterolemic venules. The dose of aspirin (60 mg/kg/day x 7 days) used to study aspirin effects on platelet and leukocyte adhesion produced complete inhibition of platelet COX-1 activity, as reflected by an absence of TXB 2 generation by aspirin-treated platelets The molecular basis for the anti-inflammatory effects of aspirin on the endothelial cell appears to involve both a platelet-independent mechanism as well as COX-1 inhibition. Endothelial cells are known to express both the constitutive (COX-1) and inducible (COX-2 isoforms of cyclooxygenase, with the latter isoform found in leukocytes as well. Although aspirin is a highly specific inhibitor for the COX-1 isoform, at high doses it can also inhibit COX-2 activity (23).
Furthermore, it has been reported that the elevated levels of COX-1 and 2-derived prostanoids (prosatcyclin and thromboxane A 2 ) detected in atherogenic models is attenuated following aspirin treatment (4, 27) . Therefore, it is possible that the blunted inflammatory and thrombogenic phenotype associated with aspirin treatment of hypercholestorolemic mice reflect an inhibition of both COX isoforms. Since aspirin has also been shown to accelerate the production of COX-2-derived anti-inflammatory mediators such as lipoxins (7, 26, 38) , which has been linked to endothelial nitric oxide synthase (26) , the NSAID may also be exerting its COX-1-and platelet-independent effects through such a pathway. Additional studies are needed to more clearly define these alternate pathways of aspirin action in the microvasculature of hypercholesterolemic mice.
Although COX-1 activity of platelets from aspirin-treated mice was almost completely inhibited, hypercholesterolemia-induced adhesion of aspirin-treated platelets to the vessel wall was unaffected, a response that contrasts with the well known inhibitory effect of aspirin on platelet aggregation (homotypic adhesion) (10, 33) . However, the significant reduction in hypercholesterolemia-induced adhesion of platelets treated with SC560, a specific COX-1 inhibitor, or genetically deficient in COX-1 (monitored in COX-1 -/-selective inhibition of platelet COX-1 activity will block platelet-vessel wall interactions. In light of our results with COX-1 -/-and SC560-treated WT HC platelets, and the divergent responses of aspirin-treated platelets, it is possible that the beneficial effects of platelet COX-1 inhibition by aspirin are offset by COX-1 independent effects of aspirin that promote platelet adhesion.
Our findings also suggest that leukocyte-associated COX-1 does not contribute to the platelet adhesion responses since we noted the adhesion of COX-1 -/-platelets in HC wild type mice (only platelets are COX-1 deficient) was nearly identical to the adhesion observed when COX-1 -/-platelets were observed in COX-1 -/-/WT HC chimeras (both platelets and leukocytes are COX-1 deficient). In both of these groups platelet adhesion was significantly lower than that observed in WT HC mice receiving matched platelets. Since nearly identical leukocyte adhesion responses to hypercholesterolemia were also noted in these two experimental groups (i.e., reduced versus WT HC), it also appears unlikely that leukocyte-associated COX-1 contributes to the hypercholesterolemia-induced leukocyte adhesion.
Our results invoke a major role for platelet-associated COX-1 activity in mediating cellcell interactions in venules of hypercholesterolemic mice. In the presence of either SC560 (but not aspirin) -treated or COX-1 -/-platelets, hypercholesterolemia-induced leukocyte adhesion was reduced, especially by platelet-bearing leukocytes, suggesting that platelet-derived COX-1 products promote these hypercholesterolemia-induced blood cell interactions, possibly through transcellular production of mediators or activation of signaling pathways that induce adhesion molecule expression and/or render platelet-bearing leukocytes more responsive to activation signals (14, 29) . Our inability to demonstrate an influence of aspirin-treated platelets on plateletleukocyte and leukocyte-vessel wall adhesion in HC venules is consistent with aspirin's reported failure to inhibit increased expression of P-selectin on platelets and platelet-leukocyte aggregation associated with several CVD, such as ischemic heart disease (31), intracoronary stenting (19) , and atherosclerosis (15) .
The coupling of nitric oxide to aspirin has resulted in a unique set of compounds (e.g., NCX-4016) that retain aspirin's anti-platelet properties but are devoid of its gastric damaging effects (9, 12, 38) . NO-releasing aspirin has been shown to inhibit thrombus formation in rats and mice (24, 35) , and to attenuate FMLP-stimulated and colitis-induced leukocyte adhesion in mesenteric rat venules (36, 37) . Supported by a grant from the National Heart, Lung and Blood Institute (R01 HL26441)
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